Navigation Links
Pharmasset Announces Proposed Public Offering of Common Stock
Date:1/18/2011

Brooklyn, NY 11220, Attention: Prospectus Department, 800-831-9146.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV).ContactRichard E. T. Smith, Ph.D. VP, Investor Relations and Corporate Communicationsrichard.smith@pharmasset.comOffice: +1 (609) 613-4181Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts, including, without limitation, statements regarding the proposed public offering and our expected use of proceeds, are "forward-looking statements" that involve risks, uncertainties and other important factors, including, without limitation, the risk that adverse events could cause the cessation or delay of the proposed offering or any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we will be unable to apply the proceeds of the shares being sold by us in the offering as presently intended, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties and important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 filed with the Securi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Positive Results from its HCV Clinical Programs
2. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
4. Pharmasset to Webcast an Investor Event from the AASLD Meeting
5. Pharmasset to Present at the JMP Healthcare Conference
6. Pharmasset to Present at the UBS Global Life Sciences Conference
7. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
8. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
9. Pharmasset Reports Fiscal Year End 2009 Financial Results
10. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
11. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 New technology in ... could allow physicians to see and assess brain tissue ... according to study authors who released their findings today ... Annual Meeting in Colorado Springs, CO. ... the field of neurointervention, a specialty that facilitates stroke ...
(Date:7/29/2014)... 2014 McGraw-Hill Education Professional, a leading global ... and medical communities, has announced the launch of the ... of the world-renowned medical education platform. ... , available for download onto all iOS and Android ... gain access to valuable AccessMedicine diagnostic resources ...
(Date:7/29/2014)... CITY and TORONTO ... EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging ... the development of improved novel formulations and ... molecules announces expansion of its pharmaceutical development ... development direction includes large molecule drugs that will ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4
... Seen Since Presentation at ASCO ... Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, Calif., Sept. ... a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 inhibitor,demonstrated antitumor ...
... Sept. 7 Roche announced today that three,clinical data ... for presentation at the 2007 Breast Cancer Symposium in ... abstracts include data from the XeNA (Xeloda in NeoAdjuvant),trial, ... Herceptin in,patients with invasive breast cancer. The third presentation ...
Cached Medicine Technology:Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 2Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 3
(Date:7/29/2014)... The Natural Multiple Sclerosis Treatment review ... to Gary M. Levin’s cure program. , Levin ... this serious disorder. Levin says that multiple sclerosis actually ... be found in patients. , Dr. Gary M. ... years, Levin has worked with patients suffering from MS. ...
(Date:7/29/2014)... 2014 Winter is here down under, ... in Sydney’s central business district. That is, until a ... transformed the otherwise ordinary day into a celebration—a celebration ... ardent advocates of The Truth About Drugs, a drug ... . They woke up the city with a rousing ...
(Date:7/29/2014)... Daily Gossip reveals in its review that ... that will permanently eliminate all the symptoms associated to this ... will banish symptoms such as mild hearing loss, as well ... patients will be gone forever. , The method will lead ... of this program says that at the end of the ...
(Date:7/29/2014)... --,The time at which heart attack patients arrive at ... research suggests. Showing up at the emergency room ... with a 13 percent higher risk for death than ... year, more than 250,000 people suffer a ST-elevation myocardial ... which is caused by a complete blockage of blood ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... regulators told a Congressional panel today that some biological ... -- are simple enough// to produce in generic versions, ... ,Generic versions of certain biologics have been ... approval came only after manufacturers conducted rigorous human clinical ...
... of governments of Western Pacific countries in fighting tuberculosis (TB), ... control the disease. ,The region has successfully met ... of TB cases and curing at least 85 percent of ... body's TB programme. ,He was speaking at a ...
... Researchers from the decades long Framingham Heart Study, say that if ... there is a good chance// of you having lessened the risk ... continue, if your parents died young, diet and exercise may well ... published in the Archives of Internal Medicine, show that middle-aged children ...
... of industrial chemicals has suggested that we may not ... prolonged use of non-stick frying// pans and baking trays; ... penetrate into our system causing health problems, they said. ... Notification and Assessment Scheme or NICNAS said it is ...
... mattresses and TVs contain possibly hazardous chemicals called polybrominated ... National Institute of Standards and Technology and the Environmental ... ,It is not yet clear how dangerous these PBDEs ... of Europe. Their structure is strikingly similar to that ...
... soldiers who are suffering from mental illness after serving ... 18 months or longer for treatment// from the National ... figures released by British Ministry of Defence (MoD) showed ... health conditions after returning from Iraq since 2003. More ...
Cached Medicine News:Health News:Caution Urged on Biologic Drugs 2Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Take Heart If Your Parents Died at a Ripe Old Age: Framingham Heart Study 2
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
... The all-new Canon CF-60DSi is an all-digital ... simple configuration, and an efficient workflow. ... mounts -- The Canon EOS-1Ds series SLR digital ... a 11.1 mega pixel resolution and the new ...
... The AIA-360 is a sophisticated Aumated Immunoassay ... This analyzer has a footprint of 16 X ... lbs. Its compact design is ideal for ... STAT testing, such as cardiac panels, as well ...
... a simple one, help physicians serve their ... the physician is provided with significantly useful ... This technical accomplishment is combined with dedicated ... The device features: High ...
Medicine Products: